Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
Mais filtros










Intervalo de ano de publicação
3.
Clin Exp Rheumatol ; 13(4): 493-5, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7586783

RESUMO

Sixty-three consecutive Behçet's syndrome patients with an acute arthritis of up to 10 days duration were treated either with azapropazone (APZ) 300 mg t.i.d. or placebo for three weeks. Twenty-eight patients (14 males, 14 females: mean age 36.2 +/- 8.1 SD years) from the APZ group and 29 patients (18 males, 11 females; mean age 34.2 +/- 8.4 SD years) from the placebo group completed the trial. At the end of the trial the arthritis persisted in 53.5% (15/28) of the APZ patients and in 41.3% (12/29) of the placebo patients (chi 2 = 0.85; NS). Six patients (6/28; 21%) from the APZ group and 9 patients (9/29; 31%) from the placebo group developed new joint involvement (chi 2 = 0.7; NS). There was no difference in the duration of arthritis between the two groups (19.9 +/- 8.3 SD days in the APZ groups vs. 19.7 +/- 8.2 SD days in the placebo group; NS). The degree of joint swelling, the tender joint score and the visual analogue score for pain significantly improved in both groups, but there was no difference in any of these parameters between the groups except for a significant difference in the visual analogue score for less pain at the first week in the azapropazone group (t = 2.23; p < 0.05). There were also no differences in the mean numbers of acetaminophen tablets used or in the CRP and ESR levels between the two groups. We conclude that azapropazone is not effective in controlling the arthritis of Behçet's syndrome.


Assuntos
Apazona/uso terapêutico , Artrite/complicações , Artrite/tratamento farmacológico , Síndrome de Behçet/complicações , Doença Aguda , Adulto , Apazona/efeitos adversos , Artrite/fisiopatologia , Método Duplo-Cego , Feminino , Humanos , Masculino , Cuidados Paliativos , Placebos , Falha de Tratamento
4.
Agents Actions ; 39 Spec No: C21-3, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8273571

RESUMO

The relationship between endoscopically observed gastric mucosal damage, elicited following repeated oral intake for 7 d of four NSAIDs, to their effects on antral and fundic production of PGE2, 6-keto-PGF1 alpha and TxB2 (assayed by GC-MS), mucosal histology and plasma concentration profiles was studied in 40 normal males. Subjects received azapropazone (APZ) 600 mg b.i.d., indomethacin (IND) 50 mg t.i.d., naproxen (NAP) 500 mg b.i.d., piroxicam (PIR) 20 mg qq.d., or one placebo capsule t.i.d. (N = 8/group). Plasma NSAIDs (HPLC) levelled at 7 d. Mucosal damage occurred in the antrum region with IND and NAP. APZ and PIR exhibited no differences compared to placebo. NAP and IND reduced all three prostanoids in the antrum while APZ and PIR were ineffective. Fundic PGE2 was reduced by IND, NAP and PIR; APZ had no effects. Thus, mucosal damage relates to effects on prostanoid production in the antrum but not in the fundus.


Assuntos
6-Cetoprostaglandina F1 alfa/metabolismo , Anti-Inflamatórios não Esteroides/efeitos adversos , Dinoprostona/metabolismo , Mucosa Gástrica/efeitos dos fármacos , Tromboxano B2/metabolismo , Adulto , Anti-Inflamatórios não Esteroides/farmacologia , Apazona/efeitos adversos , Apazona/sangue , Apazona/farmacologia , Fundo Gástrico/efeitos dos fármacos , Fundo Gástrico/metabolismo , Mucosa Gástrica/metabolismo , Humanos , Indometacina/efeitos adversos , Indometacina/sangue , Indometacina/farmacologia , Masculino , Naproxeno/efeitos adversos , Naproxeno/sangue , Naproxeno/farmacologia , Piroxicam/efeitos adversos , Piroxicam/sangue , Piroxicam/farmacologia , Antro Pilórico/efeitos dos fármacos , Antro Pilórico/metabolismo
6.
Acta Physiol Hung ; 80(1-4): 281-7, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1345197

RESUMO

The damage of the mucous membranes in the gastrointestinal tract caused by non-steroid antiinflammatory drugs are well known. The gastrointestinal microbleeding was measured by the method of Fischer and Hunt before and after the intake of indomethacin (4 x 25 mg), naproxen-sodium (4 x 275 mg), diclofenac (3 x 50 mg) and azapropazone (2 x 600 mg). In the indomethacin group microbleeding increased from 0.91 +/- 0.12 ml/24 h to 7.30 +/- 1.20 ml/h. In the naproxen-sodium group from 1.22 +/- 0.16 ml/24 h to 3.56 +/- 0.40 ml/24 h, in the diclofenac group from 0.86 +/- 0.14 ml/24 h to 3.18 +/- 0.28 ml/24 h, in azapropazone group from 0.92 +/- 0.18 ml/24 h to 2.50 +/- 0.20 ml/24 h, respectively. All non-steroid antiinflammatory drugs increased the gastric microbleeding, however, there were considerable differences in the degree of enhancement. This can be explained by the different inhibitory activities of the drugs on the cyclooxygenase enzyme activity.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Hemorragia Gastrointestinal/patologia , Adulto , Apazona/efeitos adversos , Diclofenaco/efeitos adversos , Suco Gástrico/citologia , Hemorragia Gastrointestinal/induzido quimicamente , Humanos , Indometacina/efeitos adversos , Pessoa de Meia-Idade , Naproxeno/efeitos adversos
7.
Anaesthesia ; 46(10): 828-32, 1991 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1842215

RESUMO

Eighty patients received one of three treatments after elective dental surgery involving multiple extractions. Group A received aspirin 600 mg, group B azapropazone 300 mg and group C azapropazone 600 mg. All drugs were administered in a double-blind fashion. Quality of analgesia was unsatisfactory for all treatments; over 30% of patients required supplementary analgesia with an opioid. In addition there were a large number of withdrawals from the study. There were no significant differences in analgesic efficacy between groups.


Assuntos
Apazona/uso terapêutico , Aspirina/uso terapêutico , Dor Pós-Operatória/tratamento farmacológico , Extração Dentária/efeitos adversos , Adolescente , Adulto , Apazona/efeitos adversos , Apazona/sangue , Aspirina/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Morfina/administração & dosagem , Medição da Dor
8.
Aliment Pharmacol Ther ; 5(4): 419-33, 1991 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-1777551

RESUMO

Addition of glucose and sodium citrate to azapropazone, in proportions of 1:1:1 by weight reduced gastric mucosal damage in rats and there was a trend towards reduction in radiolabelled faecal red cell loss in human volunteers compared with that with azapropazone alone. The glucose and citrate did not affect the pharmacokinetics of azapropazone, or its therapeutic efficacy. While no difference was observed in endoscopic injury and in symptomatic gastrointestinal complaints in a multicentre comparison in rheumatic patients, a striking reduction in symptoms was observed in those patients with a history of severe gastrointestinal intolerance to non-steroidal anti-inflammatory drugs.


Assuntos
Apazona/efeitos adversos , Citratos/uso terapêutico , Glucose/uso terapêutico , Úlcera Péptica/prevenção & controle , Adolescente , Adulto , Idoso , Animais , Apazona/administração & dosagem , Apazona/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Citratos/administração & dosagem , Ácido Cítrico , Endoscopia Gastrointestinal , Feminino , Mucosa Gástrica/patologia , Glucose/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Úlcera Péptica/induzido quimicamente , Ratos , Ratos Endogâmicos , Método Simples-Cego
10.
Lancet ; 2(8662): 519-22, 1989 Sep 02.
Artigo em Inglês | MEDLINE | ID: mdl-2570233

RESUMO

To test the hypothesis that non-steroidal anti-inflammatory drugs (NSAIDs) accelerate the progression of osteoarthritis by reducing synthesis of vasodilator prostaglandins, thereby diminishing joint perfusion, 105 osteoarthritis patients awaiting hip arthroplasty were treated prospectively with a strong or weak prostaglandin synthesis inhibitor, indomethacin or azapropazone, respectively. Pain and radiological joint space were monitored during the period up to arthroplasty and the condition of the excised femoral head was determined. As judged by radiological and histopathological data, the two treatment groups were at a similar pathophysiological end-point when they came to arthroplasty. In the indomethacin group the affected hips lost joint space more rapidly than did the contralateral hips, a difference not seen in the azapropazone group. The patients receiving azapropazone, who had higher concentrations of synovial vasodilator prostaglandins, took longer than the indomethacin group to reach the arthroplasty end-point. Potent inhibitors of prostaglandin synthesis may be inappropriate in the management of osteoarthritis of the hip.


Assuntos
Apazona/efeitos adversos , Articulação do Quadril/diagnóstico por imagem , Prótese de Quadril , Indometacina/efeitos adversos , Osteoartrite do Quadril/tratamento farmacológico , Triazinas/efeitos adversos , Idoso , Regeneração Óssea , Ensaios Clínicos como Assunto , Avaliação de Medicamentos , Cabeça do Fêmur/patologia , Articulação do Quadril/patologia , Humanos , Pessoa de Meia-Idade , Osteoartrite do Quadril/diagnóstico por imagem , Osteoartrite do Quadril/cirurgia , Medição da Dor , Estudos Prospectivos , Radiografia , Distribuição Aleatória , Fatores de Tempo
18.
Br J Dermatol ; 114(6): 733-5, 1986 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3718865

RESUMO

We report an episode of bone marrow hypoplasia following the administration of azapropazone to a patient stabilized on regular methotrexate for psoriasis. A pharmacokinetic interaction is postulated.


Assuntos
Apazona/efeitos adversos , Doenças da Medula Óssea/induzido quimicamente , Metotrexato/efeitos adversos , Triazinas/efeitos adversos , Adulto , Apazona/uso terapêutico , Interações Medicamentosas , Feminino , Humanos , Artropatias/tratamento farmacológico , Metotrexato/uso terapêutico , Psoríase/tratamento farmacológico
19.
Lancet ; 1(8472): 57-60, 1986 Jan 11.
Artigo em Inglês | MEDLINE | ID: mdl-2867313

RESUMO

In 3 years seventeen patients presented to one unit with renal failure associated with the use of non-steroidal anti-inflammatory drugs (NSAID). Seven patients presented with acute renal failure, in four due to acute tubular necrosis and in three to acute interstitial nephritis; all recovered when NSAID treatment was stopped. Four patients presented with symptomless renal impairment discovered during routine follow-up in a rheumatology clinic; again all improved on withdrawal of NSAID. The remaining six patients presented with chronic renal failure, a disorder not previously associated with NSAID treatment. The pattern of renal disease associated with NSAID may be more extensive than has previously been recognised. A history of NSAID use should be sought in all patients presenting with unexplained renal failure.


Assuntos
Lesão Renal Aguda/induzido quimicamente , Anti-Inflamatórios/efeitos adversos , Adulto , Idoso , Apazona/efeitos adversos , Creatinina/sangue , Feminino , Humanos , Falência Renal Crônica/induzido quimicamente , Necrose Tubular Aguda/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Naproxeno/efeitos adversos , Nefrite Intersticial/induzido quimicamente , Piroxicam , Proteinúria/induzido quimicamente , Tiazinas/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA